Two Sigma Securities’s Scinai Immunotherapeutics SCNI Stock Holding History

Two Sigma Securities’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-14,696	Closed	-$18.6K	–	1948
2025 Q3	$18.6K	Buy	+14,696	New	+$25.6K	﹤0.01%	1150
2022 Q2	–	Sell	-229	Closed	-$38K	–	2776
2022 Q1	$38K	Sell	229 -265	-54%	-$38.5K	﹤0.01%	1908
2021 Q4	$116K	Buy	+494	New	+$102K	0.01%	1159

Other funds holding SCNI

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Securities's SCNI Position: Q4 2025 in Review

Two Sigma Securities sold out of Scinai Immunotherapeutics (SCNI) in Q4 2025, closing a stake of 14,696 shares — an estimated $18.6K sold.

Two Sigma Securities first reported a position in SCNI in Q4 2021 and held it in 3 quarters. The position peaked at $116K in Q4 2021. 7 funds tracked by Wall St. Rank hold SCNI as of Q4 2025.

Two Sigma Securities reported no remaining Scinai Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
Two Sigma Securities sold 14,696 Scinai Immunotherapeutics shares in Q4 2025, an estimated $18.6K.
Two Sigma Securities first reported a position in Scinai Immunotherapeutics in Q4 2021 and held it in 3 quarters.
Two Sigma Securities's Scinai Immunotherapeutics position peaked at $116K in Q4 2021.
7 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2025.

Based on Two Sigma Securities's 13F filing for Q4 2025, filed 17 Feb 2026.